Relativity Acquisition Announces Separate Trading of Its Class A Common Stock and Warrants Effective April 4, 2022 – Form 8-K

Relativity Acquisition Corp. announces separate trading of its Class A common shares and warrants effective April 4, 2022

NEW YORK, NY, April 1, 2022 (GLOBE NEWSWIRE) — Relativity Acquisition Corp. (Nasdaq: RACYU) (the “Company”) announced today that effective April 4, 2022, holders of units sold in the Company’s IPO of 14,375,000 units completed on April 15 February 2022, may elect to trade separately the Class A common shares of the Corporation (“Class A common shares”) and the warrants included in the Units. The Class A common stock and warrants which are separated will trade on the Nasdaq Capital Market under the symbols “RACY” and “RACYW”, respectively. The unseparated units will continue to trade on the Nasdaq Global Market under the symbol “RACYU”.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities of the Company, and there will be no sale of such securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or territory.

About Relativity Acquisition Corp.

Relativity Acquisition Corp. is a blank check corporation sponsored by Relativity Acquisition Sponsor LLC, a Delaware limited liability corporation, formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more companies. The Company intends to focus on businesses in the legalized cannabis industry, including related industries such as consumer packaged goods, health and wellness, technology, pharmaceuticals, manufacturing , distribution, logistics and brand management. The management team and board of directors are comprised of veteran cannabis and finance industry executives, led by Founder, President and CEO Tarek Tabsh, known for his role as co-founder of the pharmaceutical company Oxford Cannabinoid Technologies and 15 years of investment and cannabis industry experience. .

Forward-looking statements

This press release may include, and oral statements made from time to time by representatives of the Company may include, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1933. Exchange Act of 1934, as amended. Statements regarding possible business combinations and their financing, and related matters, and all other statements other than statements of historical facts included in this press release are forward-looking statements. When used in this press release, words such as “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “could”, “plan”, “possible”, “potential”, “predict”, “project”, “should”, “would” and similar expressions, as they relate to us or our management team, identify forward-looking statements. These forward-looking statements are based on the beliefs of management, as well as assumptions made by the management of the Company and information currently available to it. Actual results could differ materially from those contemplated by the forward-looking statements due to certain factors detailed in the Company’s filings with the Securities and Exchange Commission (“SECONDAll subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are independent of the will of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the Company’s IPO filed with the SEC. undertake not to update these statements for revisions or changes after the date of this release, except as required by law.

Company Contact:

Email: [email protected]


Website: www.relativityacquisitions.com


Press inquiries: [email protected]

Comments are closed.